Last reviewed · How we verify
NCT03076476: EMPIRE-BVS
Coronary Microcirculatory and Bioresorbable Vascular Scaffolds
NA trial testing Bioresorbable Vascular Scaffolds (BVS) in CHD - Coronary Heart Disease in 36 participants. Completed in 10 March 2021.
10 March 2021
Quick facts
| Lead sponsor | Papworth Hospital NHS Foundation Trust |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 36 |
| Start date | 1 February 2017 |
| Primary completion | 10 March 2021 |
| Estimated completion | 10 March 2021 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Bioresorbable Vascular Scaffolds (BVS)
- Drug-Eluting Stent (DES) - slow
- Drug-Eluting Stent (DES) - standard(std)
Conditions studied
- CHD - Coronary Heart Disease — all drugs for CHD - Coronary Heart Disease →
- Angina, Stable — all drugs for Angina, Stable →
- Myocardial Ischemia — all drugs for Myocardial Ischemia →
Sponsor
Papworth Hospital NHS Foundation Trust
Who can join
Adults 18 to 75, any sex, with CHD - Coronary Heart Disease or Angina, Stable. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Angina and heart attacks are caused by narrowings in the coronary arteries (blood vessels) supplying the heart. These narrowings can be opened using a balloon and stent (angioplasty). Traditionally, stents are constructed from metal and are permanent. However, newer stents are being constructed from carbohydrate polymers (scaffolds), which allow them to reabsorb over time leaving no permanent implant. New data has suggested that these scaffolds appear to reduce recurrent angina and may alter the blood flow down the artery. However, it is not known whether this is due to the scaffolds themselves or the way the scaffolds are inserted. In this study we hope to measure the blood flow to the heart and assess changes in that flow during stent and scaffold insertion. It is also important to know whether these effects are durable and thus, a cohort of patients will return at 3-months to be restudied. These data are important to help us understand why blood flow is affected by stent/scaffold selection or device implantation technique and whether this results in better long-term outcomes.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Coronary Flow Variations Following Percutaneous Coronary Intervention Affect Diastolic Nonhyperemic Pressure Ratios More Than the Whole Cycle Ratios.
Aetesam-Ur-Rahman M, Zhao TX, Paques K, Oliveira J, et al · · 2022 · cited 3× · PMID 35470686 · DOI 10.1161/jaha.121.023554
Verify or expand the search:
- PubMed search for NCT03076476
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Papworth Hospital NHS Foundation Trust trials
Trials by the same sponsor.
- NCT07289100 — Novel Sensors and Artificial Intelligence for Detection of Acute Pulmonary Exacerbations in Cystic Fibrosis and Bronchie · recruiting
- NCT06433960 — Radial Artery Assessment in Surgical Coronary Revascularisation · completed
- NCT05775263 — Validation of UK Protocols to Exclude Brain Blood Flow During Normothermic Regional Perfusion (NRP) · unknown
- NCT06421792 — PrOtamIne doSing clOt imagiNg (POISON) Study · not yet recruiting
- NCT06072872 — Portable Continuous Positive Airways Pressure (CPAP) in Excessive Central Airway Collapse (ECAC) Study · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03076476 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Papworth Hospital NHS Foundation Trust
- Last refreshed: 22 April 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03076476.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing